Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of S095029-based combination therapy in advanced MSI-H/dMMR gastroesophageal junction or gastric adenocarcinoma
CTR20251423Phase 2Active
- Sponsor
- Servier
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sym021 in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, sponsored by Servier. Started Jul 2025; status: active.
02
Drugs
sym021
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on CTR20251423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251423.